Not that I have much knowledge but I couldn't help but notice the guy said the mylin sheath (the brains harmful chemichal screener) deteriorates with age but his inflammation inhibitor promotes remylination? Given the contradiction, is this therefore a statement equivalent to quackery given the sheaths lack of ability to regenerate? I mean, the sheath gets damaged, harmfull chemichals affect the brain, so inflammation happens as the brain tries to repair itself, and the alzhimers causing plaques grow in inflamed areas. This would be a lifetime drug like statins. Also think it's great what he's trying to do but he is also the most biased guy to talk to, I hope people keep positions small.
The really exciting part of the Stage 1 trial was that people were actually improving, not just stabilising. If that is repeated in the Stage 2 trial it's a big deal. How it is happening, I don't know. Yes, everyone should keep their positions small.
Also my experience of small biotech is that prices can bounce up and down for a long time and when somebody publishes a piece like this, it can drive the price up temporarily, particularly on a Monday morning when many people have caught up with their reading over the weekend. I would be inclined not to chase it.
That's a common theme I hear. That there have been lots of failures in the Alzheimers space, but it sounds like the competitors have been working on a a different solution ( stopping amyloids). TJ was saying he has been working on inflammation as the the cause or 9 years and that has not been the accepted thinking. Now that thinking seems to be changing because the solution everyone was working on (amalyoid drugs) don't work (the graveyard you described). Biotechs to me always seem like lottery tickets and I never have any view on the drug or the company, but this one seems like it could be worth a small investment. Everything is risk reward. The Stage 2 is inconclusive it's -80%. If Stage 2 is promising it's +3X and over time much more.
Some of the basic research from two decades ago in the amyloid-causes-Alzheimers field has been questioned, with allegations of doctored images being published in papers, and papers being retracted. So the long list of failures may be at least partly down to bad science.
I notice that contrarian/special situations hedge fund manager Harris Kupperman took a 1.65% of portfolio position in INMB https://hedgefollow.com/funds/Praetorian+PR+LLC, average buy price $9.09. For biotech that's a big position.
Their trial was put on investigational hold a while ago by the FDA pending "more information on long term potency", although for now this is a bit of a technicality because the trial is being conducted in Australia and Europe. There was some suggestion that the effects of the drug may increase with time, and that seems to have been the reason for the hold. It looks like they have enough cash to cover their burn rate for roughly a year, so they may need to do a raise next year. I took a small starter position; biotech investing is like investing in explorers in the mining industry, very high risk, assume the most likely outcome is that you will lose your money, although this company does have other options in its pipeline - cancer and maybe Duchenne muscular dystrophy.
Not that I have much knowledge but I couldn't help but notice the guy said the mylin sheath (the brains harmful chemichal screener) deteriorates with age but his inflammation inhibitor promotes remylination? Given the contradiction, is this therefore a statement equivalent to quackery given the sheaths lack of ability to regenerate? I mean, the sheath gets damaged, harmfull chemichals affect the brain, so inflammation happens as the brain tries to repair itself, and the alzhimers causing plaques grow in inflamed areas. This would be a lifetime drug like statins. Also think it's great what he's trying to do but he is also the most biased guy to talk to, I hope people keep positions small.
I just noticed INMB put out a press release on our favorite topic (remyelination on Oct 24th. "INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination". https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/ea021867201ex99-1_inmune.htm
The really exciting part of the Stage 1 trial was that people were actually improving, not just stabilising. If that is repeated in the Stage 2 trial it's a big deal. How it is happening, I don't know. Yes, everyone should keep their positions small.
Also my experience of small biotech is that prices can bounce up and down for a long time and when somebody publishes a piece like this, it can drive the price up temporarily, particularly on a Monday morning when many people have caught up with their reading over the weekend. I would be inclined not to chase it.
there are wast graveyards of dead anti Alzheimer projects and companies...
and it is quite wide known, that inflamation is connected to large part of health problems ...
https://www.health.harvard.edu/promotions/sumo/fighting-inflammation?utm_campaign=Inflammation_site_ad_new_image
As a side note, I'm always amazed at how much everyone knows when they start commenting.
That's a common theme I hear. That there have been lots of failures in the Alzheimers space, but it sounds like the competitors have been working on a a different solution ( stopping amyloids). TJ was saying he has been working on inflammation as the the cause or 9 years and that has not been the accepted thinking. Now that thinking seems to be changing because the solution everyone was working on (amalyoid drugs) don't work (the graveyard you described). Biotechs to me always seem like lottery tickets and I never have any view on the drug or the company, but this one seems like it could be worth a small investment. Everything is risk reward. The Stage 2 is inconclusive it's -80%. If Stage 2 is promising it's +3X and over time much more.
Some of the basic research from two decades ago in the amyloid-causes-Alzheimers field has been questioned, with allegations of doctored images being published in papers, and papers being retracted. So the long list of failures may be at least partly down to bad science.
I notice that contrarian/special situations hedge fund manager Harris Kupperman took a 1.65% of portfolio position in INMB https://hedgefollow.com/funds/Praetorian+PR+LLC, average buy price $9.09. For biotech that's a big position.
Yes, Kuppy has a position in it.
Their trial was put on investigational hold a while ago by the FDA pending "more information on long term potency", although for now this is a bit of a technicality because the trial is being conducted in Australia and Europe. There was some suggestion that the effects of the drug may increase with time, and that seems to have been the reason for the hold. It looks like they have enough cash to cover their burn rate for roughly a year, so they may need to do a raise next year. I took a small starter position; biotech investing is like investing in explorers in the mining industry, very high risk, assume the most likely outcome is that you will lose your money, although this company does have other options in its pipeline - cancer and maybe Duchenne muscular dystrophy.
The FDA trial hold was actually lifted in January, I missed that https://www.stocktitan.net/news/INMB/i-nmune-bio-announces-fda-removal-of-clinical-hold-for-alzheimer-s-4mhwendxvuhu.html